Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Colorcon
Julphar
Medtronic
UBS
Teva
Cerilliant
Dow
Boehringer Ingelheim

Generated: April 21, 2018

DrugPatentWatch Database Preview

EXONDYS 51 Drug Profile

« Back to Dashboard

Which patents cover Exondys 51, and what generic alternatives are available?

Exondys 51 is a drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and eighty-two patent family members in twenty-three countries.

The generic ingredient in EXONDYS 51 is eteplirsen. One supplier is listed for this compound. Additional details are available on the eteplirsen profile page.
Summary for EXONDYS 51
International Patents:182
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices:see details
DailyMed Link:EXONDYS 51 at DailyMed
Drug patent expirations by year for EXONDYS 51
Pharmacology for EXONDYS 51

US Patents and Regulatory Information for EXONDYS 51

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-002 Sep 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Sarepta Theraps Inc EXONDYS 51 eteplirsen SOLUTION;IV (INFUSION) 206488-001 Sep 19, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for EXONDYS 51

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,329,668 Antisense antiviral compound and method for treating picornavirus infection ➤ Try a Free Trial
8,232,384 Antisense oligonucleotides for inducing exon skipping and methods of use thereof ➤ Try a Free Trial
8,084,433 Antisense antiviral compound and method for treating ssRNA viral infection ➤ Try a Free Trial
8,450,474 Antisense oligonucleotides for inducing exon skipping and methods of use thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Healthtrust
Johnson and Johnson
Medtronic
Cipla
Covington
Fish and Richardson
AstraZeneca
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.